W. Seeger (Giessen, Germany), M. Toshner (Cambridge, United Kingdom), R. Souza (Sao Paulo, Brazil), C. Guignabert (Le Plessis-Robinson, France)
Prevention of monocrotaline-induced pulmonary vascular and myocardial remodeling by the selective neutrophil elastase inhibitor BAY 85-8501
M. Delbeck, V. Li, F. Von Nussbaum, D. Meibom, S. Golz, K. Lustig, H. Truebel, S. Schaefer (Wuppertal, Germany)
|  |
Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist
J. Gatfield, K. Menyhart, O. Nayler (Allschwil, Switzerland)
| |
Population pharmacokinetics (PK) of riociguat in patients (pts) with renal and hepatic impairment
S. Saleh, C. Becker, R. Frey, W. Mueck (Wuppertal, Germany)
|  |
Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension
J. Patel, D. Abraham, A. Nelson, A. Silverstein, L. Clapp (London, United Kingdom; Durham, United States Of America)
| |
Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension
F. Leifer, D. Omiatek, V. Malinin, J. Ong, Z. Li, P. Klecha, R. Chapman, D. Salvail, C. Laurent, W. Perkins (Monmouth Junction, United States Of America; Sherbrooke, Canada)
| |
Incorporation into lipid nanoparticles extends the duration of activity of treprostinil in an acute hypoxia rat model of pulmonary arterial hypertension
D. Omiatek, F. Leifer, V. Malinin, J. Ong, T. Henn, Z. Li, R. Chapman, D. Salvail, C. Laurent, W. Perkins (Monmouth Junction, United States Of America; Sherbrooke, Canada)
| |
Treprostinil prodrugs for pulmonary arterial hypertension evaluated in cAMP profiling studies in live CHO-K1 cells
K. Chen, J. Ong, V. Malinin, F. Leifer, D. Omiatek, Z. Li, R. Chapman, W. Perkins, R. Gupta (Monmouth Junction, United States Of America)
| |
MicroRNA-155 controls pulmonary artery fibroblast cell signalling and proliferation in a knockout mouse model: A role in pulmonary arterial hypertension
N. McGlinchey, C. Bradley, C. McSharry, A. Peacock, D. Welsh (Glasgow, United Kingdom)
| |
Endothelial-to-mesenchymal transition in pulmonary hypertension
B. Ranchoux, C. Rucker-Martin, F. Antigny, C. Péchoux, A. Hautefort, H. J. Bogaard, P. Dorfmüller, F. Lecerf, N. Raymond, S. Chat, E. Fadel, A. Houssaini, S. Adnot, G. Simonneau, M. Humbert, S. Cohen-Kaminsky, F. Perros (Le Plessis-Robinson, Le Kremlin-Bicetre, Jouy-en-Josas, Créteil, France; Amsterdam, Netherlands)
| |
Increased endothelial-derived microparticles in ventilator-induced lung injury
E. Letsiou, S. Sammani, J. G. Garcia, S. M. Dudek (Chicago, Tucson, United States Of America)
| |
Immune signatures in pulmonary arterial hypertension
F. Perros, D. Montani, B. Girerd, A. Sefarian, P. Dorfmuller, I. Klingel-Schmitt, M. Vocelle, A. Courtier, O. Filipe-Santo, G. Parmentier, S. Perez, C. Suberbielle, S. Caillat-Zucman, G. Simonneau, M. Humbert, S. Cohen-Kaminsky (Le Plessis Robinson, Le Kremlin Bicêtre, Grenoble, Paris, France)
| |
Molecular study of genetic modifiers in patients with pulmonary arterial hypertension
G. Pousada, A. Baloira, D. Valverde (Vigo, Pontevedra, Spain)
| |
Female pulmonary arterial hypertension is associated with decreased microRNA96 expression
E. Wallace, K. Mair, L. Long, X. D. Yang, N. Morrell, A. H. Baker, M. R. MacLean (Glasgow, Cambridge, United Kingdom)
| |
The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension
D. Morales-Cano, C. Menendez, J. Moral-Sanz, B. Barreira, R. Jimenez, L. Moreno, A. Cogolludo, J. Cortijo, J. Duarte, F. Perez-Vizcaino (Madrid, Granada, Valencia, Spain)
| |
Smooth muscle microparticles as novel biomarkers of vascular remodelling and inflammation in pulmonary arterial hypertension
R. Gurung, L. Clapp, N. Klein (London, United Kingdom)
| |
Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations
V. Malinin, Z. Li, R. Chapman, F. Leifer, D. Omiatek, J. Ong, D. Salvail, C. Laurent, W. Perkins (Monmouth Junction, United States Of America; Sherbrooke, Canada)
| |
Neuron-derived orphan receptor 1 mediated human pulmonary arterial smooth muscle cells proliferation via cyclin D1
D. X. Zeng, C. G. Wang, W. Lei, J. A. Huang (Suzhou, China)
| |
Expression and role of the nerve growth factor NGF in severe pulmonary hypertension
F. Coste, C. Toussaint, M. Dubois, A. Courtois, C. Guibert, R. Marthan, J. P. Savineau, B. Muller, V. Freund-Michel (Bordeaux, Pessac, France)
| |
PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience
A. Volkov, N. Yudkina, E. Nikolaeva, I. Kurmukov (Moscow, Russian Federation)
| |